Recent Updates
Recently added Catalysts
ETON Positive Sentiment Score: 65/100

Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

Wednesday, May 3, 2023 2 min read
Key Takeaway: Eton Pharmaceuticals, Inc. has announced a date to report its first quarter financial results for 2023, scheduled for May 11. The company will host a conference call and live audio webcast to discuss these results, allowing participant interaction through live and emailed questions. Eton focuses on developing treatments for rare diseases and currently has three FDA-approved products and several candidates in the pipeline.

Market Sentiment Analysis

POSITIVE FACTORS

  • Eton Pharmaceuticals is set to report first quarter 2023 financial results, indicating ongoing business activity.
  • The company has three FDA approved products, showcasing its established presence in the market.
  • Eton is actively engaging with investors through various communication methods.

Full Press Release Details

DEER PARK, Ill., May 03, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2023 financial results on Thursday, May 11, 2023. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).
Register* (Audio Only) Click Here
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
* Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has three FDA approved products in ALKINDI SPRINKLE®, Carglumic Acid tablets, and Betaine Anhydrous for oral solution, and four late-stage pipeline candidates under development with dehydrated alcohol injection, ZENEO® hydrocortisone autoinjector, ET-400, and ET-600. In addition, the Company receives royalties on three FDA-approved products and is entitled to receive milestone payments on other products. For more information, please visit our website at www.etonpharma.com.
Lisa M. Wilson, In-Site Communications, Inc.
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals

Frequently Asked Questions

When will Eton Pharmaceuticals report Q1 2023 results?

Eton Pharmaceuticals will report its first quarter 2023 financial results on May 11, 2023.

How can I access the Eton Pharmaceuticals webcast?

The live webcast can be found in the Investors section of Eton's website.

Will there be a Q&A session during the conference call?

Yes, management will answer live questions as well as emailed questions from investors.

What types of treatments does Eton Pharmaceuticals focus on?

Eton Pharmaceuticals specializes in developing treatments for rare diseases.

How many FDA-approved products does Eton have?

Eton currently has three FDA-approved products on the market.

Tags: ETON Viatris Investor Conferences Healthcare Eton Pharmaceuticals Q1 2023 financial results FDA approved products rare diseases
Last updated: May 3, 2023